WHAT IS KNOWN AND OBJECTIVE: Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management. CASE SUMMARY: The patient was a 70-year-old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969 mg/dL after 22 months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels. WHAT IS NEW AND CONCLUSION: Severe HTG may occur in everolimus-treated patients. Prescription of the appropriate therapy can allow patients to continue this medication.

Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) / V. De Gennaro Colonna, C. Pavanello, F. Rusconi, A. Sartore-Bianchi, S. Siena, S. Castelnuovo, C.R. Sirtori, G. Mombelli. - In: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. - ISSN 1365-2710. - 43:1(2018), pp. 114-116. [10.1111/jcpt.12588]

Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

V. De Gennaro Colonna;C. Pavanello;A. Sartore-Bianchi;S. Siena;S. Castelnuovo;C.R. Sirtori;G. Mombelli
2018

Abstract

WHAT IS KNOWN AND OBJECTIVE: Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management. CASE SUMMARY: The patient was a 70-year-old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969 mg/dL after 22 months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels. WHAT IS NEW AND CONCLUSION: Severe HTG may occur in everolimus-treated patients. Prescription of the appropriate therapy can allow patients to continue this medication.
everolimus; fenofibrate; hypertriglyceridaemia; mammalian target of rapamycin inhibitors
Settore MED/06 - Oncologia Medica
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
2017 De Gennaro Colonna et al, Journal_of_Clinical_Pharmacy_and_Therapeutics.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 232.44 kB
Formato Adobe PDF
232.44 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Colonna_et_al-2018-Journal_of_Clinical_Pharmacy_and_Therapeutics.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 313.46 kB
Formato Adobe PDF
313.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/551960
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact